**New In-house Assay:**

**COVID-19 (SARS-CoV-2, N) Salivary IgG**

The Institute for Interdisciplinary Salivary Bioscience Research (IISBR) will offer a new COVID-19 (SARS-CoV-2) Nucleocapsid Protein (N-protein) specific IgG antibody assay for use in saliva. The N-protein is the most immunodominant protein in the coronavirus family. This assay can be used to support research studies to investigate seroprevalence and incidence related to the spread of the SARS-CoV-2 infection. The easy-to-collect, non-invasive nature of saliva sampling facilitates the identification of prior COVID-19 exposure, enabling seroprevalence research studies to occur at a population-based level. IgG in saliva is derived from serum, so specificity and reactivity of salivary IgG reflects serum IgG reactivity. Antibody testing for the SARS-CoV-2 N-protein in saliva provides a valuable alternative over traditional blood-based serology and samples.

**Effective date:** December 11th, 2020

**Volume Requirements:** 50ul for singlet, 100ul for duplicate

**Assay Features:**
- 92% sensitivity
- 97.6% specificity
- Best if used in tandem with the Total IgG Assay

**Test methodology:** Qualitative ELISA

**Turnaround time:** 2-3 days

A summary of all tests offered by the IISBR laboratory services can be found at: [https://iisbr.uci.edu/](https://iisbr.uci.edu/)

IISBR services are designed primarily for research purposes. We do not offer clinical testing services and are currently not a CLIA certified lab provider.